IL1B and alcoholic hepatitis: As the literature around the use of IL-1 inhibitors is evolving at a rapid rate, we conducted a global systematic review to appraise the existing literature on the use of IL-1 inhibitors like anakinra, rilonacept and canakinumab in alcoholic hepatitis in terms of clinical benefits, outcomes and adverse effects.